Key highlights
- AZURE-4 study met the primary endpoint with 59% of patients on a 300 mg weekly dose achieving success
- Control arm participants in the delayed-treatment group showed a 0% response rate at Week 24
- Clinical results included patients with advanced disease, with 53% of participants having cirrhosis
- Company will use AZURE-4 and AZURE-1 data as the basis for a U.S. registration package
- Long-term data presented at AASLD showed sustained viral suppression through 108 weeks of treatment
Phase 3 AZURE-4 Clinical Outcomes
Mirum Pharmaceuticals achieved a significant clinical milestone as its Phase 3 AZURE-4 trial for brelovitug met its primary endpoint in chronic hepatitis delta virus (HDV) patients. The study compared two dosing regimens against a delayed-treatment arm. At the 24-week mark, 59% of participants receiving the 300 mg weekly dose and 44% of those on the 900 mg monthly dose reached the composite endpoint of alanine aminotransferase (ALT) normalization and virologic response. Notably, none of the patients in the control group achieved this metric. The study population was characterized by high disease severity, with 53% of participants having cirrhosis at baseline.
Strategic Significance of Results
- Completes the clinical data requirements for the company's upcoming U.S. registration package for brelovitug
- Data presented at AASLD shows sustained improvements in liver stiffness and viral suppression up to 108 weeks
- Validates the efficacy of a subcutaneous monoclonal antibody in treating severe viral hepatitis
- Positions Mirum to compete in the specialized adult hepatology market with a potential first-in-class therapy
- Demonstrated efficacy in treatment-naive patients with high baseline viral loads exceeding 6 log10 IU/mL
Business Overview and Pipeline
Based in Foster City, California, Mirum Pharmaceuticals is a commercial-stage biotechnology firm specializing in rare liver diseases. The company's portfolio includes Livmarli and Cholbam, which target various cholestatic liver conditions in pediatric and adult populations. Mirum has focused its pipeline on addressing unmet needs in hepatology where few therapeutic options exist. The successful development of brelovitug represents a major expansion into the hepatitis delta space, a niche within the broader infectious disease sector. This advancement aligns with the company's strategy to diversify its revenue streams beyond its established rare disease treatments.
Financial and Market Context
Mirum Pharmaceuticals currently carries a market capitalization of approximately $6.08 billion, supported by growing commercial revenues. For the most recent quarter, the company reported revenue of $185.72 million, contributing to an annual revenue figure of $521.31 million. The stock has shown positive momentum recently, with a monthly price increase of 14.54% and a relative strength index of 59.8. This clinical success provides a potential future revenue catalyst as the company transitions from Phase 3 data analysis toward formal regulatory submission. The strong trial results may influence the company's competitive standing in the biotechnology sector.
Down 1.7% since our story on 10 Nov: $93.18 when we broke it → $91.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $82.24 |
|---|---|
| 20 Oct | $85.07 |
| 21 Oct | $83.44 |
| 22 Oct | $83.10 |
| 23 Oct | $80.39 |
| 26 Oct | $83.27 |
| 27 Oct | $85.56 |
| 28 Oct | $85.81 |
| 29 Oct | $86.39 |
| 30 Oct | $85.00 |
| 2 Nov | $85.74 |
| 3 Nov | $87.03 |
| 4 Nov | $96.97 |
| 5 Nov | $93.54 |
| 6 Nov | $93.72 |
| 9 Nov | $93.18 |
| 10 Nov | $94.42 |
| 11 Nov | $94.61 |
| 12 Nov | $93.33 |
| 13 Nov | $93.99 |
| 16 Nov | $91.58 |
| Share price | $93.18 |
|---|---|
| Market cap | $6.1B |
| Revenue (annual) | $521M |
| 1-month price change | +14.54% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Mirum Pharmaceuticals, Inc. announcing positive Phase 3 results for its HDV treatment candidate brelovitug.
Track Mirum Pharmaceuticals, Inc. live
Get the next Mirum Pharmaceuticals, Inc. SEC filing seconds after it lands.

